Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEWI: Dostarlimab in Localized dMMR/MSI-H Gastric or GEJ Adenocarcinoma
NCT06059495Phase 2Recruiting
- Sponsor
- GERCOR
- Start
- Jan 2024
- Primary completion
- Sep 2028
- Countries
- 2
01
Overview
A Phase 2 trial of dostarlimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by GERCOR. Started Jan 2024; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06059495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059495.